Clinical Trials in Pennsylvania

Showing 2281-2300 of 9,383 trials

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NCT06240728

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

Metastatic Malignant Neoplasm

NextPoint Therapeutics, Inc.144 participantsStarted Jan 2024

Baltimore, Maryland, United States • Boston, Massachusetts, United States • The Bronx, New York, United States +5 more locations

COMPLETEDPhase 295 miles

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221

This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).

Non Hodgkin LymphomaFollicular LymphomaIndolent Lymphoma+6 more

University of Maryland, Baltimore17 participantsStarted Oct 2017

Miami, Florida, United States • Baltimore, Maryland, United States • Milwaukee, Wisconsin, United States

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Find Trials by Condition in Pennsylvania

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

ExaStim Upper Limb Home Use Clinical Validation Study

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Clinical Investigation of the Next-Generation Intraocular Lens

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Gluten Technology and Education for Celiac Health

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Cough Reduction in IPF With Nalbuphine ER

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients